- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02266953
The Use of a Communication Tool About Diet
The Use of a Communication Tool About Diet in Public Health Nurse Consultations at the Child Health Centre When the Child is Aged 10 Months to 2 Years
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Norway, as other Nordic countries, has a long-standing tradition of extensive and freely available health care for children under school age at the child health centre. Virtually all parents with small children use these child health centres, having regular encounters with public health nurses. This service aims at promoting health and preventing disease in the population. However, when comes to content and performance of conversation about food and feeding practices there are no guidelines regarding how to adapt the information to the individual child and to his or her family after infancy and up to two years of age.
The overall purpose of this study is to promote optimal nutrition for the child based on the public health nurse's family-focused conversations at the child health centre.
The design of the study is a cluster randomized controlled trial. Statistics Norway has on the basis of a systematic match drawn samples of five pairs of municipalities in Norway. It is random which municipality in each match is extracted respectively to intervention or control municipality.
Public health nurses on child health centres within intervention municipalities will use a communication tool about food and feeding practices in their encounters with participating children and parents when the child is 10-, 12- and 15-18 months old. In the control municipalities corresponding encounters will be as usual, without use of the actual communication tool. The parents will answer a food frequency questionnaire on behalf of their child when the child is 10 months old (baseline) and at the age of two years (final measurement).
Sample size consideration: The aim of the study is to reveal change in vegetable intake. The investigators keep level of statistical significance at the customary 5 % and statistical power of 80 % (beta equal to 20 %), the investigators would need 176 children in each group to reveal the change described above as statistically significant.
The investigators expect some drop out and given that their estimate might be slightly higher, the investigators want to enroll 300 children in each group to make sure our study is sufficiently powered.
Plan for missing data: Concerning missing data the investigators will use mixed models for repeated measure, imputation of missing data will therefore not be necessary. All data will be analysed according to Intention to treat (ITT) analysis.
Analytical principles: Unadjusted (or crude) differences between intervention and control group will be assessed with t-tests (for continuous variables) and Chi-square tests (when we test for association between pairs of categorical data).
In case of continuous outcome variables, the investigators will model the differences between groups (scores from the questionnaires) using uni- and multiple linear regression methods.
All regression models will be conditioned on district variable and not individual level because the randomization was performed on district variable level.
The investigators treat this study as an exploratory analysis, however, they will fit several statistical models and perform several tests therefore a correction for multiple testing will be performed. P-values < 0,01 will be considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, N-0130
- Oslo and Akershus University College of Applied Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All parents and their children, regardless of the parents' country of origin or native language, who visit the child health centre when the particular child is six months old.
- Parents that perceive themselves to have sufficient knowledge of Norwegian language to understand the information sheet in Norwegian about the study.
Exclusion Criteria:
- Parents and their children who do not visit the child health centre when the particular child is six months old.
- Parents who do not experience to have sufficient knowledge of Norwegian to read and understand the written Norwegian information about the study.
- The youngest twin and the midst and youngest triplet if the child is a twin or triplet.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Use of communication tool about diet
The children and parents in the intervention group are visiting consultations at the child health centre where the public health nurses use a communication tool about diet in order to promote dialogue about themes concerning food and feeding practices.
This intervention is carried out at consultations when the child is 10-, 12- and 15-18 months old.
|
The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family.
This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
|
ACTIVE_COMPARATOR: Treatment as usual
The children and parents in the control group are visiting consultations at the child health centre where the public health nurses will conduct the consultations as usual and without use of the actual communication tool about diet.
The consultations are carried out when the child is 10-, 12- and 15-18 months old.
|
The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase in the daily intake of vegetables
Time Frame: An expected average of 14 months from baseline
|
Metrics are based on parents answering Food Frequency Questionnaires (FFQs) on behalf of their child, at baseline and at endpoint. In addition to questions about the child's diet, there are questions about the child's weight and length at birth, six months, 10 months and 2 years. Both FFQs are updated versions, based on validated and standardized FFQs used in earlier national dietary surveys among infants and toddlers in Norway, conducted under the auspices of the University of Oslo, the Norwegian Food Safety Authority and the Norwegian Ministry of Health and Care Services (Spedkost [Infant Diet] 2006-2007 (IS-1635); Småbarnskost [Toddler Diet] 2007 (IS-1731)). Analyses of the data will be conducted by use of a diet calculation system. The expectation is an increased intake of 15 g vegetables daily, based on average intake of vegetables of 50 g daily at the age of 1 year according to Spedkost [Infant Diet] 2006-2007 (IS-1635) and Småbarnskost [Toddler Diet]2007 (IS-1731). |
An expected average of 14 months from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decreased proportion of saturated fat consumed daily
Time Frame: An expected average of 14 months from baseline
|
The metrics and analyses are in accordance with those described in the section of primary outcome measure. According to the literature, with the intervention the investigators expect a change of 10 % which means the consumption would go down to 10,8 %. Given the small proportions the investigators would need very large numbers of children to reveal such changes as statistically significant. With significance level of 5 % and power of 80 %, they would need 12 426 in each group which is not feasible for us at this stage. Therefore, the secondary aim will be treated as an exploratory analysis and the investigators only aim to describe the proportion of saturated fats consumed daily. |
An expected average of 14 months from baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body weight
Time Frame: An expected average of 14 months from baseline
|
The metrics and analysis are in accordance with what is described under the section of primary outcome measure.
This outcome measure will be treated as an exploratory analysis.
|
An expected average of 14 months from baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Kari Glavin, PhD, Oslo Metropolitan University
- Study Chair: Sølvi Helseth, Professor, Oslo Metropolitan University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2014/726
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dietary Intervention
-
Fundacio d'Investigacio en Atencio Primaria Jordi...WithdrawnDietary Intervention | Iodine Deficiency | Pregnancy JailSpain
-
University of KielCompleted
-
University of ReadingUnknown
-
University of MalagaAndaluz Health ServiceUnknownPhysical Activity | Dietary Modification | Patient Fall | Fragility | Multimodal Intervention | Other Metabolic DiseasesSpain
-
University of ParmaFoundation for Liver Research; Azienda Ospedaliero-Universitaria di Parma; National... and other collaboratorsNot yet recruitingObesity | Cardiometabolic Health | Individual Variability in (Poly)Phenol Metabolism | Personalized Dietary InterventionItaly
-
Hull University Teaching Hospitals NHS TrustUniversity of HullCompletedType 2 Diabetes | Dietary InterventionUnited Kingdom
-
University of ReadingUnknownDietary Habits | Dietary ModificationUnited Kingdom
-
University of ReadingCompletedDietary Habits | Dietary ModificationUnited Kingdom
-
The University of Tennessee, KnoxvilleCompletedDietary Assessment | 24-hour Dietary Recall | Dietary Restraint | Social DesirabilityUnited States
Clinical Trials on Use of communication tool about diet
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH); Massachusetts General Hospital; Beth...Enrolling by invitationHIV-infection/AIDSUnited States
-
Boston Children's HospitalUnknownPediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)United States
-
AstraZenecaCompletedType 2 Diabetes MellitusUnited States
-
West China HospitalBeijing Tiantan Hospital; First Affiliated Hospital of Chongqing Medical University and other collaboratorsCompletedStroke | Cardiovascular Disease | Primary PreventionChina
-
Groupe Hospitalier de la Region de Mulhouse et...Completed
-
Stanford UniversityVarian Medical SystemsEnrolling by invitationQuality of LifeUnited States
-
University of Massachusetts, WorcesterBoston University; National Heart, Lung, and Blood Institute (NHLBI)WithdrawnCovid19 | Vaccination
-
University of Massachusetts, WorcesterNational Institute on Aging (NIA); University of Utah; Boston CollegeActive, not recruitingPalliative Care | Interdisciplinary Communication | Caregivers | Deprescriptions | Hospices | Poly Pharmacy | Prescription Drug OveruseUnited States
-
Icahn School of Medicine at Mount SinaiAlbert Einstein College of Medicine; National Institute on Minority Health... and other collaboratorsCompletedGenetic Diseases, Inborn | Genetic Predisposition to DiseaseUnited States
-
AstraZenecaParexelTerminatedType II Diabetes MellitusUnited Kingdom